RYTM

113.0603.20%
DW

David W. J. McGirr

Independent Director

Mr. David W. J. McGirr, MBA, also known as Davie, serves as Director of Design & Development at Illumina Digital Limited. Mr. McGirr served as an Independent Director of Menlo Therapeutics Inc. since November 2017 until March 2020. He served as a Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals Inc. from March 2013 to June 2014. He served as the Chief Financial Officer and Senior Vice President of Cubist Pharmaceuticals Inc. (formerly, TerraGen Discovery, Inc.) since November 2002 to March 2013 and also served as its Principal Accounting Officer until March 2013. Mr. McGirr has experience across multiple industries and private equity. He served as Treasurer of Cubist Pharmaceuticals from November 2002 to January 2003. Prior to joining Cubist in 2002, he served as the President and Chief Operating Officer of Hippo Inc. from 1999 to 2002. From 1996 to 1999, he served as the President of GAB Robins North America Inc. and served as its Chief Executive Officer from 1997 to 1999. He was a Private Equity Investor from 1995 to 1996. He served as the Chief Financial Officer, Chief Administrative Officer and Managing Director of S.G. Warburg & Co. Inc. from 1992 to 1995. From 1978 to 1995, he served in various positions within S.G. Warburg Group and served as its Chief Financial Officer (U.S.), Chief Administrative Officer and Managing Director of S.G. Warburg & Co. Inc. He joined Cubist in 2002. He had been a Director of Insmed Incorporated since October 2013 until May 13, 2026. He has been a Director of Rhythm Holding Company, LLC since December 2015. He serves as a Director of Illumina Digital Limited. He has been Independent Director of Rhythm Pharmaceuticals, Inc. since November 2015. He served as a Director at Relypsa, Inc. from 2013 to September 2016. He served as a Director at MOTUS THERAPEUTICS, INC. since December 16, 2015. He served as a Director of LifeCell Corp. from November 2007 to May 2008 and Sorrento Tech, Inc. (formerly known as Roka Bioscience, Inc.) from December 2013 to January 2018. He served as a Director of Hippo Inc. from 1999 to 2003. He had been an Independent Director of X4 Pharmaceuticals, Inc. (formerly, Arsanis, Inc.) since September 2017 until August 22, 2025. He is a regular guest lecturer at Middlesex University and has validated their Film Production and Technical Arts degree. He was a guest lecturer at Goldsmiths College, the RCA and Birkbeck College, University of London. He was nominated for a TV Craft BAFTA in 2007 as Best New Media Developer. Mr. McGirr received a B.Sc. in Civil Engineering from the University of Glasgow and received an MBA from The Wharton School at the University of Pennsylvania.

Positions